leadf
logo-loader
viewScancell Holdings PLC

Scancell Holdings takes crucial step in Covid vaccine preparations by teaming up with Cobra Biologics

The agreement covers the good manufacturing pracatice (GMP) production of plasmid DNA needed to generate the inoculation against SARS-CoV-2

Scancell Holdings PLC -

Cobra Biologics will manufacture Scancell Holdings PLC’s (LON:SCLP) COVID-19 vaccine ready for a phase I clinical trial.

The agreement covers the good manufacturing practice (GMP) production of plasmid DNA needed to generate the inoculation against SARS-CoV-2.

GMP production represents a “crucial development” in that it ensures the DNA vaccine can be produced at scale and to therapeutic-grade standards. Cobra has a “long-established plasmid production platform along with in-house expertise [that] will ensure the highest quality”, Scancell said.

The preparations are part of the lead up to the COVIDITY clinical study that forms the centrepiece of work being carried out by Scancell, the University of Nottingham and Nottingham Trent University, funded by Innovate UK.

"Our collaboration with Cobra is critical to us moving forward with our novel SARS-CoV-2 vaccine into the planned phase I clinical trial, COVIDITY,” said Scancell's chief executive, Dr Cliff Holloway.

“Cobra has the expertise needed to produce clinical-grade plasmid at scale and we look forward to working with them to advance our vaccine and demonstrate its potential effectiveness and protection against COVID-19."

Scancell's DNA vaccine will target the SARS-CoV-2 to generate both an immune response and neutralising antibodies against the virus.

The jab has the potential to provide long-lasting immunity against COVID-19 by generating protection not only against this strain, but also against new strains of coronavirus that may arise in the future.

Quick facts: Scancell Holdings PLC

Price: 11.5 GBX

LSE:SCLP
Market: LSE
Market Cap: £93.75 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read